0001818382-23-000193.txt : 20231212 0001818382-23-000193.hdr.sgml : 20231212 20231212160945 ACCESSION NUMBER: 0001818382-23-000193 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231208 FILED AS OF DATE: 20231212 DATE AS OF CHANGE: 20231212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sander Dale A. CENTRAL INDEX KEY: 0001878193 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39532 FILM NUMBER: 231481338 MAIL ADDRESS: STREET 1: 11304 EMPIRE LAKES DRIVE CITY: RALEIGH STATE: NC ZIP: 27617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Humacyte, Inc. CENTRAL INDEX KEY: 0001818382 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851763759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-313-9633 MAIL ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200716 4 1 wk-form4_1702415371.xml FORM 4 X0508 4 2023-12-08 0 0001818382 Humacyte, Inc. HUMA 0001878193 Sander Dale A. 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713 0 1 0 0 CFO and Chief Corp. Deve. Off. 0 Stock Options (right to buy) 2.80 2023-12-08 4 A 0 301000 0 A 2033-12-08 Common Stock 301000 301000 D Stock Options (right to buy) 10.28 2023-12-11 4 A 0 525 0 A 2023-12-11 2030-12-14 Common Stock 525 2100 D The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027. On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant. /s/ Dale A. Sander 2023-12-12